INS and fatty liver disease: In this way, (C16:0) ceramides may contribute to the selective insulin resistance paradox, wherein the insulin-resistant liver fails to suppress glucose production but continues to stimulate lipogenesis, which is a central mechanism in the pathophysiology of hepatic steatosis and type 2 diabetes [96, 97].